206 related articles for article (PubMed ID: 33636586)
1. COVID-19-related arrhythmias and the possible effects of ranolazine.
Chukwunyere U; Sehirli AO; Abacioglu N
Med Hypotheses; 2021 Apr; 149():110545. PubMed ID: 33636586
[TBL] [Abstract][Full Text] [Related]
2. Ranolazine in Cardiac Arrhythmia.
Saad M; Mahmoud A; Elgendy IY; Richard Conti C
Clin Cardiol; 2016 Mar; 39(3):170-8. PubMed ID: 26459200
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine and its Antiarrhythmic Actions.
Polytarchou K; Manolis AS
Cardiovasc Hematol Agents Med Chem; 2015; 13(1):31-9. PubMed ID: 26245658
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias.
Shenasa M; Assadi H; Heidary S; Shenasa H
Card Electrophysiol Clin; 2016 Jun; 8(2):467-79. PubMed ID: 27261835
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Late Sodium Current as an Innovative Antiarrhythmic Strategy.
Bengel P; Ahmad S; Sossalla S
Curr Heart Fail Rep; 2017 Jun; 14(3):179-186. PubMed ID: 28455610
[TBL] [Abstract][Full Text] [Related]
6. The antiarrhythmic effects of ranolazine.
Foster NJ; Haines DE
Rev Cardiovasc Med; 2009; 10 Suppl 1():S38-45. PubMed ID: 19898287
[TBL] [Abstract][Full Text] [Related]
7. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
Maier LS
J Cardiovasc Pharmacol; 2009 Oct; 54(4):279-86. PubMed ID: 19333133
[TBL] [Abstract][Full Text] [Related]
8. Ranolazine: an antianginal drug with antiarrhythmic properties.
Tamargo J; Caballero R; Delpón E
Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
[TBL] [Abstract][Full Text] [Related]
9. Ranolazine: a new approach to treating an old problem.
Reddy BM; Weintraub HS; Schwartzbard AZ
Tex Heart Inst J; 2010; 37(6):641-7. PubMed ID: 21224931
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine: effects on ischemic heart.
Rognoni A; Barbieri L; Cavallino C; Bacchini S; Veia A; Degiovanni A; Rametta F; Nardi F; Lazzero M; Lupi A; Bongo AS
Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914
[TBL] [Abstract][Full Text] [Related]
11. Changes in global electrical heterogeneity associated with dofetilide, quinidine, ranolazine, and verapamil.
Stabenau HF; Shen C; Tereshchenko LG; Waks JW
Heart Rhythm; 2020 Mar; 17(3):460-467. PubMed ID: 31539628
[TBL] [Abstract][Full Text] [Related]
12. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
Thadani U
Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
[TBL] [Abstract][Full Text] [Related]
13. Role of ranolazine in heart failure: From cellular to clinic perspective.
Kaplan A; Amin G; Abidi E; Altara R; Booz GW; Zouein FA
Eur J Pharmacol; 2022 Mar; 919():174787. PubMed ID: 35114190
[TBL] [Abstract][Full Text] [Related]
14. Update on evidence for treatment with ranolazine in stable angina.
Carbone F; Montecucco F; Mach F
Swiss Med Wkly; 2013; 143():w13874. PubMed ID: 24163124
[TBL] [Abstract][Full Text] [Related]
15. Ranolazine therapy in drug-refractory ventricular arrhythmias.
Curnis A; Salghetti F; Cerini M; Vizzardi E; Sciatti E; Vassanelli F; Villa C; Inama L; Raweh A; Giacopelli D; Bontempi L
J Cardiovasc Med (Hagerstown); 2017 Jul; 18(7):534-538. PubMed ID: 28368882
[TBL] [Abstract][Full Text] [Related]
16. New Anti-Anginal Drugs: Ranolazine.
Cavallino C; Facchini M; Veia A; Bacchni S; Rosso R; Rognoni A; Rametta F; Lupi A; Bongo AS
Cardiovasc Hematol Agents Med Chem; 2015; 13(1):14-20. PubMed ID: 25544118
[TBL] [Abstract][Full Text] [Related]
17. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.
Reiffel JA; Camm AJ; Belardinelli L; Zeng D; Karwatowska-Prokopczuk E; Olmsted A; Zareba W; Rosero S; Kowey P;
Circ Arrhythm Electrophysiol; 2015 Oct; 8(5):1048-56. PubMed ID: 26226999
[TBL] [Abstract][Full Text] [Related]
18. Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.
Moreno JD; Yang PC; Bankston JR; Grandi E; Bers DM; Kass RS; Clancy CE
Circ Res; 2013 Sep; 113(7):e50-e61. PubMed ID: 23897695
[TBL] [Abstract][Full Text] [Related]
19. Electrophysiologic basis for the antiarrhythmic actions of ranolazine.
Antzelevitch C; Burashnikov A; Sicouri S; Belardinelli L
Heart Rhythm; 2011 Aug; 8(8):1281-90. PubMed ID: 21421082
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine reduces atrial fibrillatory wave frequency.
Black-Maier EW; Pokorney SD; Barnett AS; Liu P; Shrader P; Ng J; Goldberger JJ; Zareba W; Daubert JP; Grant AO; Piccini JP
Europace; 2017 Jul; 19(7):1096-1100. PubMed ID: 27756767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
